Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran

Key Inclusion Criteria:

1. Willing and able to provide written informed consent prior to participating in thestudy.
2. Female subjects ≥18 to 55 years of age (inclusive) and premenopausal as defined by themodified STRAW criteria (specifically, Stage -5 [menses variable to regular] throughStage 1 [≥2 skipped cycles and an interval of amenorrhea ≥60 days]).
3. Able to communicate clearly with the Principle Investigator (PI) and staff; able toread English, complete questionnaires, and understand study procedures.
4. Able to complete all screening period evaluations, stay in the clinic testing facilityfor minimum of 4 hours following dose of BMT.
5. In good general health, free from clinically significant medical or psychiatricillness or disease (as determined by medical/surgical history, physical examination,weight, 12-lead ECG, and clinical laboratory tests).

Key Exclusion Criteria:

1. Postmenopausal female, designated by having amenorrhea for ≥12 months.
2. Has current or recent (within 6 months) history of gastrointestinal disease, or anysurgical or medical condition such as Crohn's disease or liver disease, that couldpotentially alter the absorption, metabolism, or excretion of the study drug.
3. Has any clinically significant medical condition, physical exam finding, or ECGabnormality, or clinically significant abnormal value for hematology, serology,clinical chemistry, or urinalysis at Screening, or at admission to the study center,as assessed by the PI.
4. Has any of the following:

• History or current diagnosis of uncontrolled hypertension defined as: Two (2)sequential assessments (at least 5 minutes apart and no more than 15 minutes apart) atlevels >140 mmHg SBP or 90 mmHg DBP and/or treatment for hypertension that has beenchanged at least once in the 4 weeks before Screening.
• Renal dysfunction (creatinine clearance < 80 mL/min using Cockcroft Gaultcalculation).

5. History or presence of malignancy within the past 5 years, with the exception ofadequately treated localized skin cancer (basal cell or squamous cell carcinoma),which is allowed.